Latest RFP From Kazakh

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Substance Natalizumab (L04aa23), S.C. Dosage Form as Part of an Open House Model.

Special Purpose Mobile Containers

(Pu-10797/23) Road Bitumen

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Medicinal Products with the Active Ingredient Tiotropium Bromide, in the Dosage Form for Inhalation (R03bb04) (Open House)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tezepelumab, Atc R03dx11 for the Period June 1St, 2023 - May 31St, 2025

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredients Formoterol, Glycopyrronium Bromide and Budesonide (R03al11) - (Open House Model).

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Ibuprofen (M01ae01) as Part of a So-Called Open House Model.

System, Method and Application Training and other Similar Training Related to Social and Healthcare Services

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Promethazine (N05cm22) as Part of a So-Called Open House Model.

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Goserelin, Atc L02ae03 for the Period June 1St, 2023 - May 31St, 2025